| 臺大學術典藏 |
2021-09-04T05:16:46Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:42Z |
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients with Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
|
Huang C.-F.; Hung C.-H.; Cheng P.-N.; Bair M.-J.; Huang Y.-H.; JIA-HORNG KAO; Hsu S.-J.; Lee P.-L.; Chen J.-J.; Chien R.-N.; Peng C.-Y.; Lin C.-Y.; Hsieh T.-Y.; Cheng C.-H.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T05:16:42Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:17Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T05:16:16Z |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Liu C.-J.; Dai C.-Y.; JIA-HORNG KAO; Chuang W.-L.; Lin H.-C.; Yu M.-L. |
| 臺大學術典藏 |
2021-09-01T01:54:01Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Hsu C.; Yang T.-S.; Huo T.-I.; Hsieh R.-K.; Yu C.-W.; Hwang W.-S.; Hsieh T.-Y.; Huang W.-T.; Chao Y.; Meng R.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-07-03T03:35:14Z |
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
Liu C.-J.; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; Chen C.-L.; PEI-JER CHEN; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:33:31Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.;Shih Y.-L.;Yang S.-S.;Lin C.-L.;Fang Y.-J.;Cheng P.-N.;Chen C.-Y.;Peng C.-Y.;Hsieh T.-Y.;Chiu Y.-C.;Su T.-H.;Liu C.-J.;Yang H.-C.;Pei-Jer Chen;Chen D.-S.;Kao J.-H.; Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:26Z |
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan
|
CHEN-HUA LIU; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:23Z |
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
|
CHEN-HUA LIU; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:21Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
CHEN-HUA LIU; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:20Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
CHEN-HUA LIU; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; Liu C.-J.; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:12Z |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU; Lee M.-H.; Liu C.-J.; Dai C.-Y.; Kao J.-H.; Chuang W.-L.; Lin H.-C.; Yu M.-L. |
| 臺大學術典藏 |
2021-05-24T03:41:41Z |
2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension
|
Huang W.-C.;Hsu C.-H.;Sung S.-H.;Ho W.-J.;Chu C.-Y.;Chang C.-P.;Chiu Y.-W.;Wu C.-H.;Chang W.-T.;Lin L.;Lin S.-L.;Cheng C.-C.;Wu Y.-J.;Wu S.-H.;Hsieh T.-Y.;Hsao-Hsun Hsu;Fu M.;Dai Z.-K.;Kuo P.-H.;Hwang J.-J.;Cheng S.-M.;Tsoc Pulmonary Hypertension Committee; Huang W.-C.; Hsu C.-H.; Sung S.-H.; Ho W.-J.; Chu C.-Y.; Chang C.-P.; Chiu Y.-W.; Wu C.-H.; Chang W.-T.; Lin L.; Lin S.-L.; Cheng C.-C.; Wu Y.-J.; Wu S.-H.; Hsieh T.-Y.; HSAO-HSUN HSU; Fu M.; Dai Z.-K.; Kuo P.-H.; Hwang J.-J.; Cheng S.-M.; TSOC pulmonary hypertension committee |
| 臺大學術典藏 |
2021-05-06T01:25:13Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; CHIEN-CHING HUNG; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:43Z |
Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir
|
Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; TUNG-HUNG SU; Tseng T.-C.; Hsu C.-S.; Lin H.H.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:38Z |
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
|
Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; TUNG-HUNG SU; Tseng T.-C.; Lin H.H.; Wang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:33Z |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
|
Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; TUNG-HUNG SU; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:47:32Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
TUNG-HUNG SU; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2021-03-09T01:43:16Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; TUNG-HUNG SU; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-02T01:41:18Z |
Volume holographic optical element for light sheet fluorescence microscopy
|
Hsieh T.-Y.;Vyas S.;Wu J.-C.;Yuan Luo; Hsieh T.-Y.; Vyas S.; Wu J.-C.; YUAN LUO |
| 臺大學術典藏 |
2021-01-15T03:46:55Z |
Percutaneous transgastric traction-assisted esophageal endoscopic submucosal dissection: A randomized controlled trial in a porcine model
|
Chen P.-J.; Huang W.-C.; HSIU-PO WANG; Chang W.-K.; Hsieh T.-Y.; Shih S.-C.; Wang H.-Y.; Liu C.-Y. |
| 臺大學術典藏 |
2021-01-15T02:46:18Z |
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan
|
Yu K.-H.; Chen D.-Y.; Chen J.-H.; Chen S.-Y.; Chen S.-M.; Cheng T.-T.; SONG-CHOU HSIEH; Hsieh T.-Y.; Hsu P.-F.; Kuo C.-F.; Kuo M.-C.; Lam H.-C.; Lee I.-T.; Liang T.-H.; Lin H.-Y.; Lin S.-C.; Tsai W.-P.; Tsay G.J.; Wei J.C.-C.; Yang C.-H.; Tsai W.-C. |
| 國立成功大學 |
2021 |
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
|
Huang, C.-F.;Kuo, H.-T.;Chang, T.-S.;Lo, C.-C.;Hung, C.-H.;Huang, C.-W.;Chong, L.-W.;Cheng, P.-N.;Yeh, M.-L.;Peng, C.-Y.;Cheng, Cheng C.-Y.;Huang, J.-F.;Bair, M.-J.;Lin, C.-L.;Yang, C.-C.;Wang, S.-J.;Hsieh, T.-Y.;Lee, T.-H.;Lee, P.-L.;Wu, Wu W.-C.;Lin, C.-L.;Su, W.-W.;Yang, S.-S.;Wang, C.-C.;Hu, J.-T.;Mo, L.-R.;Chen, Chen C.-T.;Huang, Y.-H.;Chang, Chang C.-C.;Huang, C.-S.;Chen, G.-Y.;Kao, C.-N.;Tai, C.-M.;Liu, C.-J.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Kao, J.-H.;Lin, H.-C.;Chuang, W.-L.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen, Chen C.-Y.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Lo, C.-C.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Yu, M.-L. |
